Neurostimulation device maker Halo Neuroscience said today it raised $13 million in a Series B round of financing to support its Halo Sport neurostim headset designed to improve muscle memory acquisition from athletic training.
The funding round was led by TPG and joined by existing investors Lux Capital, JAZZ Venture Partners and XFund, the San Francisco-based company said.
“This round of funding is a testament to the proven science behind Halo, and to the enormous potential of the company in the areas of consumer and medical neuromodulation. Halo has pioneered a powerful new means of improving human performance, and we’re proud to stand behind its technology and leadership,” TPG’s Heath Lukatch, who joined Halo’s board, said in a prepared statement.
The company’s flagship device, the Halo Sport, is designed to deliver neurostimulation to the motor cortex in a 20 minute neuropriming session which Halo Neuroscience claims induces a temporary state of hyperplasticity that allows neural pathways from the motor cortex to the muscles to be optimized and strengthened.
“Halo is a leader in unlocking the potential in the brain’s capacity to learn, and stands as one of the most exciting new technologies I’ve seen in recent years. Currently used by elite athletes at the highest level of sport, we anticipate a wider audience to develop among those seeking to improve a broad range of human activity, from sports-specific skills to key cognitive functions,” board exec chair Peter Gotcher said in a prepared statement.
Halo Neuroscience said that the device is currently being used by organizations including the San Francisco Giants, the US Olympic Ski Team and US Special Operations Forces.
“What started in 2013 as a team of neuroscientists who believed in the power of neurostimulation has led to a global movement. We are proud to be the torchbearers in the space and are excited we now have the financial fuel to build and launch two new products that will further unlock human potential,” Halo co-founder Dr. Daniel Chao said in a press release.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.